European Medicines Agency accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

GSK

2 December 2022 - Application includes data from key Phase 3 trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy outcomes.

GSK today announced that the EMA validated the marketing authorisation application for momelotinib, a potential new oral treatment for myelofibrosis.

Read GSK press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Europe , Dossier